NLRP3 and depressive symptom measurement: (2022) demonstrated that the antidepressant fluoxetine counteracted isolation-exacerbated brain and cardiovascular pathology in an AD-like depression model by activating Nrf2/HO-1, an antioxidant pathway that limits ROS accumulation and thereby inhibits NLRP3 signaling (113).